Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome

Paul Maddison, John Newsom-Davis, Kerry R Mills

Abstract

Objective—To assess the distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome (LEMS) to identify the most sensitive muscle to use in routine examination.

Methods—Surface recorded compound muscle action potential (CMAP) amplitudes were made from abductor digiti minimi, abductor pollicis brevis, anconeus, biceps brachii, and trapezius in 10 patients with LEMS. The effect of 3,4-diaminopyridine (3,4-DAP) was recorded in each muscle in nine patients. CMAP amplitudes were measured at rest and immediately after 10 seconds maximal voluntary contraction in each muscle. Values were compared with results obtained from 12 healthy controls.

Results—Resting CMAP amplitudes were reduced in at least one muscle in all patients compared with controls, most markedly in abductor digiti minimi and anconeus. The administration of 3,4-DAP resulted in significantly improved resting CMAP amplitudes in trapezius only. After maximal voluntary muscle contraction, characteristic increments in CMAP amplitude of over 100% above resting values were seen in abductor digiti minimi and abductor pollicis brevis in seven patients, anconeus and biceps brachii in five patients. No patient had this level of increment in trapezius.

Conclusion—Despite predominantly proximal limb weakness seen clinically in patients with LEMS, the most sensitive muscles for detecting characteristic electrophysiological abnormalities of low resting CMAP amplitude and increment of over 100% after 10 seconds maximal voluntary contraction are abductor digit minimi, abductor pollicis brevis, and anconeus.

Keywords: Lambert-Eaton myasthenic syndrome; compound muscle action potential

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of neuromuscular transmission, characterised by proximal muscle weakness, absent tendon reflexes, and autonomic dysfunction. About 60% of patients have an associated small cell lung cancer. Diagnosis of LEMS is made principally on: (1) the specific clinical features of proximal lower limb weakness, depressed tendon reflexes with post-tetanic potentiation, and autonomic disturbances, most notably dryness of the mouth; (2) the presence of autoantibodies directed against P/Q-type voltage gated calcium channels, detectable in 85% to 95% of cases; and (3) characteristic abnormalities found on neurophysiological examination.

The classic diagnostic electrophysiological abnormalities in LEMS are a reduced amplitude of the resting compound muscle action potential (CMAP), a decrement in CMAP amplitude at low rates of repetitive nerve stimulation, and an increment in CMAP amplitude, typically over 100%, after either high rates of nerve stimulation or 10 to 15 seconds maximal voluntary contraction. Usually, the abductor digiti minimi muscle is used in electrophysiology to diagnose and assess the severity of LEMS, although several small series have recorded from trapezius, flexor carpi ulnaris, anconeus, tibialis anterior and extensor digitorum brevis. As the condition of LEMS is characterised by weakness that is typically proximal in nature, we aimed to define the electrophysiological range in LEMS by comparing proximal and distal recordings from five separate muscle groups in the upper limb. We used electrophysiological recordings to see if proximal muscles show a more marked abnormality on testing than distal muscles, as is often seen clinically.

Materials and methods

Patients

Ten patients with LEMS were studied (five men, five women; mean age 57.7, range 31 to 76), all of whom were under regular follow up in our department. One patient had had a pneumonectomy for small cell lung cancer in 1989 with no subsequent recurrence of the tumour. None of the other patients had detectable malignancy (mean duration of follow up 7.8 years; range 1 to 16 years). Proximal upper limb weakness occurred during the course of the illness in all cases. At the time of initial diagnosis, all patients had the characteristic electrophysiological abnormalities of LEMS of a low resting CMAP amplitude (in abductor digiti minimi) and incremental responses of over 100% after 10 seconds maximal voluntary contraction. Antibodies to P/Q-type voltage gated calcium channels were detected in serum samples of nine out of the 10 patients. Nine patients were treated with 3,4-diaminopyridine (3,4-DAP) at the time of testing; for these patients, initial electrophysiological recordings were made at least 10 hours after the last dose of 3,4-DAP to allow for adequate drug washout. In addition, eight of the patients were taking prednisolone and azathioprine and...
two were taking prednisolone alone; no changes were made to these treatments before or during the study.

Identical electrophysiological studies were performed in 12 healthy controls (eight men, four women; mean age 45.4 years; range 26 to 76 years). The study was approved by the central Oxford research ethics committee.

**ELECTROPHYSIOLOGICAL STUDIES**

Measurements of peak to peak CMAP amplitudes were made from abductor digitii minimi, abductor pollicis brevis, anconeus, biceps brachii, and trapezius in each patient. Supramaximal electrical stimuli (pulse duration 0.1 ms) were delivered using standard bipolar surface electrodes: the ulnar nerve supplying abductor digitii minimi and the median nerve supplying abductor pollicis brevis were stimulated at the wrist; the radial nerve innervating anconeus was stimulated just proximal to the elbow joint; the upper half of the brachial plexus (C5, C6, and C7) supplying biceps brachii via the musculocutaneous nerve was stimulated at the wrist; the spinal accessory nerve innervating the trapezius was stimulated in the posterior triangle of the neck, at the midpoint of the sternocleidomastoid muscle. Circular Ag/AgCl surface recording electrodes 1 cm in diameter were taped in a belly-tendon arrangement over each muscle in turn. Muscle signals were amplified (Medelec Mysyro) and filtered with a bandpass of 3 Hz to 5 kHz. Skin surface temperature was measured with a digital thermometer (Jenway) and maintained above 32°C throughout the experiment. The percentage increment seen after voluntary contraction was calculated from the formula:

\[ \text{Percentage increment} = \left( \frac{\text{CMAP (postexercise)} - \text{CMAP (pre-exercise)}}{\text{CMAP (pre-exercise)}} \right) \times 100\% \]

The mean result of two successive recordings was calculated for each muscle in all patients. An identical series of electrophysiological recordings were made one hour after the ingestion of 10 mg 3,4-DAP in the nine patients who were already receiving this treatment before the study.

**DATA ANALYSIS**

The values of resting CMAP amplitudes in each muscle and the percentage change in amplitude after 10 seconds maximal voluntary contraction in patients with LEMS were compared with normal values seen in the control patients. Statistical significance was determined using the Mann-Whitney U test. The significance of the improvement in muscle responses after 3,4-DAP was also determined using Wilcoxon signed rank tests.

**Results**

**RESTING MUSCLE RESPONSES**

The amplitudes of resting muscle responses were significantly lower in all five muscle groups compared with controls, most markedly in abductor digitii minimi and anconeus (table 1). All patients with LEMS had at least one CMAP amplitude measurement that was lower than the minimum recorded response in the same muscle in controls. The distribution of electrophysiological abnormality was the same in cancer associated LEMS (patient 2; see table 1) as in patients with LEMS without cancer. Values of CMAP amplitude from proximal muscles were more variable both among patients with LEMS and controls. Mean resting CMAP amplitudes were increased in all five muscles after the administration of 3,4-DAP (table 2), although this increase was only significant in the trapezius (p=0.008, Wilcoxon signed rank test).

**INCREMENTAL RESPONSES**

After 10 seconds maximal voluntary contraction, increments of over 100% in CMAP amplitudes were made from abductor digitii minimi, abductor pollicis brevis, anconeus, biceps brachii, and trapezius in each patient. Supramaximal electrical stimuli (pulse duration 0.1 ms) were delivered using standard bipolar surface electrodes: the ulnar nerve supplying abductor digitii minimi and the median nerve supplying biceps brachii were stimulated at the wrist; the radial nerve innervating anconeus was stimulated just proximal to the elbow joint; the upper half of the brachial plexus (C5, C6, and C7) supplying biceps brachii via the musculocutaneous nerve was stimulated at the wrist; the spinal accessory nerve innervating the trapezius was stimulated in the posterior triangle of the neck, at the midpoint of the sternocleidomastoid muscle. Circular Ag/AgCl surface recording electrodes 1 cm in diameter were taped in a belly-tendon arrangement over each muscle in turn. Muscle signals were amplified (Medelec Mysyro) and filtered with a bandpass of 3 Hz to 5 kHz. Skin surface temperature was measured with a digital thermometer (Jenway) and maintained above 32°C throughout the experiment. The percentage increment seen after voluntary contraction was calculated from the formula:

\[ \text{Percentage increment} = \left( \frac{\text{CMAP (postexercise)} - \text{CMAP (pre-exercise)}}{\text{CMAP (pre-exercise)}} \right) \times 100\% \]

The mean result of two successive recordings was calculated for each muscle in all patients. An identical series of electrophysiological recordings were made one hour after the ingestion of 10 mg 3,4-DAP in the nine patients who were already receiving this treatment before the study.

**Table 1** Neurophysiological measurements from the right arm in patients with LEMS and controls

<table>
<thead>
<tr>
<th>Subject</th>
<th>ADM (mV)</th>
<th>APB (mV)</th>
<th>Anconeus (mV)</th>
<th>Biceps (mV)</th>
<th>Trapezius (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3.64 (4.43)***</td>
<td>5.61 (4.92)**</td>
<td>0.67 (1.03)***</td>
<td>1.24 (1.04)**</td>
<td>4.3 (1.45)***</td>
</tr>
<tr>
<td>2</td>
<td>5.28 (4.43)***</td>
<td>6.51 (4.92)**</td>
<td>0.68 (1.03)***</td>
<td>3.14 (1.04)**</td>
<td>5.36 (1.45)***</td>
</tr>
<tr>
<td>3</td>
<td>8.61 (4.43)***</td>
<td>17.14 (4.92)**</td>
<td>0.86 (1.03)***</td>
<td>5.36 (1.04)**</td>
<td>8.6 (1.45)***</td>
</tr>
<tr>
<td>4</td>
<td>4.21 (4.43)***</td>
<td>2.61 (4.92)**</td>
<td>0.22 (1.03)***</td>
<td>1.98 (1.04)**</td>
<td>2.2 (1.45)***</td>
</tr>
<tr>
<td>5</td>
<td>1.37 (4.43)***</td>
<td>2.61 (4.92)**</td>
<td>0.32 (1.03)***</td>
<td>3.54 (1.04)**</td>
<td>4.1 (1.45)***</td>
</tr>
<tr>
<td>6</td>
<td>2.12 (4.43)***</td>
<td>2.84 (4.92)**</td>
<td>absent (1.03)***</td>
<td>0.29 (1.04)**</td>
<td>4.36 (1.45)***</td>
</tr>
<tr>
<td>7</td>
<td>10.21 (4.43)***</td>
<td>12.41 (4.92)**</td>
<td>1.42 (1.03)***</td>
<td>14 (1.04)**</td>
<td>10 (1.45)***</td>
</tr>
<tr>
<td>8</td>
<td>14.6 (4.43)***</td>
<td>2.61 (4.92)**</td>
<td>3.56 (1.03)***</td>
<td>0.49 (1.04)**</td>
<td>12.3 (1.45)***</td>
</tr>
<tr>
<td>9</td>
<td>0.7 (4.43)***</td>
<td>3.8 (4.92)**</td>
<td>0.71 (1.03)***</td>
<td>1.04 (1.04)**</td>
<td>3.6 (1.45)***</td>
</tr>
<tr>
<td>10</td>
<td>4.64 (4.43)***</td>
<td>4.08 (4.92)**</td>
<td>0.44 (1.03)***</td>
<td>2.8 (1.04)**</td>
<td>9.1 (1.45)***</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>5.34 (4.43)***</td>
<td>6.02 (4.92)**</td>
<td>0.99 (1.03)***</td>
<td>3.39 (4.04)**</td>
<td>6.21 (3.45)***</td>
</tr>
<tr>
<td>Controls</td>
<td>17.43 (4.41)***</td>
<td>17.36 (6.24)**</td>
<td>7.02 (4.47)**</td>
<td>9.58 (6.6)**</td>
<td>14.72 (4.42)**</td>
</tr>
</tbody>
</table>

Control values are mean (SD) (range) (n=12).

*p<0.001; **p<0.003; ***p<0.0001; significantly reduced v controls (Mann-Whitney U test).

ADM = abductor digitii minimi; APB = abductor pollicis brevis.

**Table 2** Compound muscle action potential amplitudes measured before and one hour after 3,4-diaminopyridine

<table>
<thead>
<tr>
<th>Muscle</th>
<th>Pre 3,4-DAP</th>
<th>Post 3,4-DAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADM</td>
<td>5.34 (4.43)***</td>
<td>5.67 (5.21)***</td>
</tr>
<tr>
<td>APB</td>
<td>6.02 (4.92)**</td>
<td>8.47 (8.14)**</td>
</tr>
<tr>
<td>Anconeus</td>
<td>0.99 (1.03)***</td>
<td>1.32 (1.26)***</td>
</tr>
<tr>
<td>Biceps</td>
<td>3.39 (4.04)**</td>
<td>3.48 (4.76)**</td>
</tr>
<tr>
<td>Trapezius</td>
<td>6.21 (3.45)**</td>
<td>7.71 (4.29)**</td>
</tr>
</tbody>
</table>

Values are mean (SD) (n=9).

*p<0.008; significantly improved following 10 mg 3,4-diaminopyridine (Wilcoxon signed rank test).

ADM = abductor digitii minimi; APB = abductor pollicis brevis; 3,4-DAP = 3,4-diaminopyridine.
Electrophysiological abnormality in Lambert-Eaton myasthenic syndrome

Amplitude above resting values were present in at least one muscle in nine of the 10 patients with LEMS. The remaining patient had increments of about 50% in abductor pollicis brevis and biceps. All control patients had increments of less than 43% in all muscle groups. The most sensitive muscle to demonstrate classic postexercise augmentation of CMAP amplitude typical of LEMS was abductor digiti minimi, with a mean increment of 348% (range 19.2% to 1414%). The least sensitive muscle tested in the patients with LEMS was trapezius (mean increment 27%; range 5.7% to 78.2%). Increments of >100% were seen in seven patients in abductor digiti minimi and abductor pollicis brevis, five patients in anconeus and biceps, and in no patient in trapezius (figure). Three patients had increments >100% in four muscles; in each case, the only muscle not to show this level of increment was trapezius. In one case (patient 7), typical post exercise CMAP amplitude increase>100% was seen only in anconeus and a further case (patient 8) had a diagnostic increment only in abductor pollicis brevis. After 3,4-DAP, CMAP amplitude increments after maximal voluntary contraction in all five muscle groups were not significantly different than before treatment.

Discussion

In this series of patients with LEMS, we have shown that the characteristic EMG abnormalities of low resting CMAP amplitude with augmentation >100% after maximal voluntary contraction are most commonly found in distal rather than proximal muscles. This does not correlate with the typical clinical features of proximal limb weakness, which is usually more profound than distal weakness. In a series of 50 patients with LEMS, 39 (78%) had upper limb weakness in the course of their illness; this was irrespective of whether or not there was an associated malignancy. It was also noted in these patients that upper limb weakness affected proximal muscles in particular and only a few patients noticed distal weakness.

Although the major clinical feature in LEMS is proximal lower limb weakness (present in 100% of patients), we did not record peripheral electrophysiological responses from proximal leg muscles for two main reasons: firstly, it is technically difficult to stimulate nerves lying deep below fascial planes proximally in the lower limb that will reproducibly evoke supramaximal muscle responses; secondly, to excite deeply situated nerves the stimulus must be of long duration and this makes the procedure unacceptably painful for the patient. It is common practice to use abductor digiti minimi or abductor pollicis brevis for measurements of response to treatment and as a marker of severity and progression of disease. By our comparisons with other, more proximal muscles in individual patients with LEMS, we have been able to show that abductor digiti minimi is the most sensitive muscle for detecting electrophysiological changes of LEMS and is therefore the most suitable muscle to test in studies involving patients with LEMS. Treatment with 3,4-DAP has previously been shown to improve resting CMAP amplitude in abductor digiti minimi, abductor pollicis brevis and biceps. Our study indicates that 3,4-DAP also has a beneficial effect on anconeus and trapezius but of all five upper limb muscles tested, the only significant improvement was demonstrated in trapezius.

It is feasible that the results obtained in our experiments in patients with LEMS receiving immunosuppression are not entirely comparable with electrophysiological measurements recorded in untreated patients with LEMS. It is possible that prednisolone, in improving neuromuscular transmission, has a more pronounced effect on proximal rather than distal muscles. This would result in larger resting CMAP amplitudes and less marked incremental responses in proximal muscles. However, electrophysiological measurements recorded in two patients before and after starting treatment with prednisolone showed more marked improvement in resting CMAP amplitude and reduced increment in abductor digiti minimi compared to trapezius, suggesting that prednisolone does not exclusively improve the characteristic EMG abnormalities seen in LEMS in proximal muscles alone. In all our patients, improvement in strength was detectable clinically in both proximal and distal muscles after initiation of immunosuppression, which also resulted in improvement in bulbar and autonomic symptoms in some cases.

Several earlier studies on patients with LEMS have reported varying degrees of characteristically abnormal electrophysiological responses in different muscle groups, but these experiments were performed on only two patients. In another report, anconeus was compared with abductor digiti minimi and found to show more pronounced characteristic
changes but this comparison was made in only four patients with LEMS.11

The detectable electrophysiological abnormality which is most marked distally in LEMS is by contrast with myasthenia gravis, in which studies have shown that repetitive nerve stimulation in proximal muscles such as trapezius or deltoid is more sensitive in detecting decrement of CMAP amplitude.16–19 It is possible that distal muscles of the upper limb have a lower safety factor for neuromuscular transmission than proximal muscles and therefore display greater incremental responses after exercise in LEMS. However, this does not explain why most patients have clinically detectable weakness in a proximal distribution.

During electrical stimulation of the larger proximal muscles, there is a degree of movement artefact that is not seen in particular in distal muscles and there is a risk that a stimulus given after a period of maximal voluntary contraction is not fully supramaximal as the stimulator may have moved from its original position while recording a supramaximal response at rest. This may have been a factor in the testing of one of our healthy controls, who recorded a decrement of 28.8% in biceps after the testing of one of our healthy controls, who recorded a decrement of 28.8% in biceps after a period of maximal voluntary contraction. One limiting factor relating to this is the degree of pain caused by stimulating deep seated nerves sufficiently to produce a supramaximal muscle response. Both patients with LEMS and control patients found stimulation of nerves supplying proximal muscles more painful than stimulation of nerves innervating distal muscles.

When stimulating the brachial plexus at Erb’s point, the CMAP recorded by electrodes over the biceps may also contain contributions from other, nearby muscles that are activated by branches from the upper brachial plexus and therefore the CMAP amplitude of the biceps may not be a pure response only from this muscle. As a result, the degree of augmentation seen after exercise may not be as marked as that seen in hand muscles. However, it is surprising that trapezius, a muscle that is often weak in patients with LEMS, did not show significant augmentation after exercise in our series as the spinal accessory nerve is superficial at the point of stimulation and can be maximally stimulated with pulses of width 0.1 ms, thereby minimising the stimulation of other surrounding muscles which may have reduced the degree of CMAP augmentation.

It has been shown that maximal voluntary contraction is more sensitive, less painful, and technically easier than 20 Hz repetitive nerve stimulation in detecting abnormal augmentation in LEMS20 and was therefore the preferred method in our study. However, errors in recording maximum augmentation could have arisen because it is more difficult to be certain that maximal voluntary contraction has been achieved in proximal muscles compared with distal muscles. It is important to deliver the second stimulus immediately after the end of maximal voluntary contraction21 because the size of the incremental response diminishes greatly in the first few seconds.22 Any delay in evoking the postexercise augmented CMAP would therefore result in a falsely low increment.

Augmentation of CMAP amplitude after maximal voluntary contraction greater than 100% is not found in all muscles tested in all patients with LEMS as shown by this study and therefore it is important to establish the most sensitive muscle to test when diagnosing and monitoring severity of disease in LEMS. Patients with increments in CMAP amplitude greater than 100% in some muscles typically have more pronounced abnormalities in distal than proximal muscles. In our series, increments in every muscle in all control patients were less than 50%, as were mean values plus 2.5 SD (figure). This suggests that an incremental responses of 50% rather than 100% could be sufficient to diagnose LEMS with the same specificity over control patients.

We therefore recommend testing abductor digit minimi at rest and after 10 seconds maximal voluntary contraction. If the findings are inconclusive, abductor pollicis brevis should be examined next and then anconeus. If the results from our series are equally applicable to those obtained when testing patients at first presentation before starting treatment, then a positive diagnosis of LEMS based on characteristic electrophysiological findings will be made in at least 90% of patients if abductor digit minimi, abductor pollicis brevis, and anconeus are tested. This should provide a quick, effective, sensitive, and accurate electrophysiological technique for monitoring patients with LEMS. Further incremental tests on biceps and trapezius are probably not worthwhile unless there is a diagnostic uncertainty with respect to myasthenia gravis. Other, more complicated and time consuming investigations such as stimulated single fibre EMG23 may not be necessary to confirm the diagnosis.

A “soap bubble” tumour in the brain: isolated cerebral immunocytoma

A 45 year old woman who had always been in good health experienced abnormal temperature sensations in the right arm and leg for one year. When she subsequently started to complain of clumsiness of the right hand and difficulties in finding the right words, she was referred to a neurologist. A discrete expressive dysphasia and slight right sided pyramidal tract dysfunction were noticed. Brain MRI showed a large contrast enhancing sharply demarcated tumour with multiple cysts in the left parietal lobe (figure A). There was no surrounding oedema. The neurosurgeon completely extirpated a gelatinous tumour with a diameter of 7 cm. On pathological examination large eosinophilic islands of protein and perivascular cuffs of tumour cells were found (figure B; haematoxylin and eosin originally ×25). The tumour proved to be a low grade lymphoplasmacytoid lymphoma (REAL classification) producing IgM light chain (lambda) immunoglobulins (figure B, inset; haematoxylin and eosin originally ×175). Postoperative MRI showed no residual tumour. No lymphoma was found in the bone marrow, thorax, and abdomen. Moreover, laboratory values were normal and no paraproteins were found in serum or urine. She was treated with whole brain radiotherapy.

MARTIN J B TAPHOORN
CEES A F TULLEKEN
GERARD H JANSEN
JEAN MICHEL J KRUL
University Hospital Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands and Gooi-Noord Hospital, PO Box 900, 1250 CA Laren, The Netherlands

Correspondence to: Dr Martin J B Taphoorn, Department of Neurology, University Hospital Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands.
Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome

Paul Maddison, John Newsom-Davis and Kerry R Mills

J Neurol Neurosurg Psychiatry 1998 65: 213-217
doi: 10.1136/jnnp.65.2.213

Updated information and services can be found at:
http://jnnp.bmj.com/content/65/2/213

These include:

References
This article cites 21 articles, 7 of which you can access for free at:
http://jnnp.bmj.com/content/65/2/213#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

  Drugs: CNS (not psychiatric) (1945)
  Immunology (including allergy) (1943)
  Neuromuscular disease (1311)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/